Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 786 across all filing types
Latest filing 2016-06-18 Director's Dealing
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2016-06-18 English
PRIMARY DOCUMENT
Director's Dealing
2016-06-18 English
PRIMARY DOCUMENT
Director's Dealing
2016-06-18 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 14, 2016, reporting the submission of matters to a vote of security holders at the company's annual general meeting. It details the voting results on the election of directors, approval of an amendment to the stock incentive plan, and ratification of the appointment of the independent auditor. The content is focused on official voting results from a shareholder meeting, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4050 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the appropriate classification is DVA with high confidence.
2016-06-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 27, 2016, by Lipocine Inc. It reports Regulation FD disclosures about presentation materials for clinical data at a medical conference. The document includes a poster exhibit related to clinical data but does not contain financial statements or detailed financial analysis. The length is 2371 characters, which is short and primarily announces the presentation and attaches the materials. This fits the description of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not qualify as an Annual Report, Earnings Release, or other detailed financial report. It is not a report publication announcement since it includes the materials as an exhibit, but the main purpose is disclosure under Regulation FD.
2016-05-27 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K, a current report filed with the SEC. It includes an update about the company's corporate presentation used for investor meetings and attaches the presentation as Exhibit 99.1. The document does not contain financial statements or detailed financial analysis but rather announces the update and provides the presentation. The length is short (2203 characters), and the content is primarily an announcement of an updated investor presentation. According to the rules, such documents are classified as Investor Presentation (IP) filings when they include the presentation itself. Therefore, the correct classification is Investor Presentation (IP).
2016-05-16 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.